# Not Lost in Translation

Page: https://stenobird.com/podcast/the-persistence-lab-7666293/not-lost-in-translation
Text version: https://stenobird.com/podcast/the-persistence-lab-7666293/not-lost-in-translation.md
Podcast: [The Persistence Lab](https://stenobird.com/podcast/the-persistence-lab-7666293)
Published: 2026-05-28T09:00:00+00:00
Episode link: https://www.abbvie.com/who-we-are/our-stories/the-persistence-lab-podcasts.html
Audio file: https://pscrb.fm/rss/p/audio-delivery.cohostpodcasting.com/audio/e6f8ee87-47be-4a8e-a2cd-6c7f13dff165/episodes/7d333f33-9ff0-4e62-96c1-1b7ad3dbd5cd/episode.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-persistence-lab-7666293/episodes/not-lost-in-translation
Duration seconds: 1218

## Resource

Why do some patients with autoimmune disease respond to treatment while others may not? Understanding these insights can offer scientists potential clues about the underlying cause of disease. This episode, sponsored by AbbVie, explores the approaches scientists use to help drive progress in immunology research like reverse translation – a process that works from “bedside to bench” using clinical observation and patient data to inform and refine drug development earlier on in the process. Not intended for UK audiences. To learn more about AbbVie’s efforts in immunology, visit:  https://www.abbvie.com/science/areas-of-focus/immunology.html

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-persistence-lab-7666293/episodes/not-lost-in-translation/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-persistence-lab-7666293/not-lost-in-translation.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.